Gene Analysis (mpl Proto-Oncogene, Thrombopoietin Receptor) Sequence Analysis Of Exon 10 in Pennsylvania
Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.
Top Providers in Pennsylvania
| Provider | Medicare | Services |
|---|---|---|
| Brookside Clinical Laboratory Inc | $181.50 | 1.5K |
| Unity Holding Groups Llc | $181.50 | 1.1K |
| Quest Diagnostics Of Pennsylvania,... | $181.50 | 63 |
| Quest Diagnostics Venture Llc | $181.50 | 56 |
| Associated Clinical Laboratories | $181.50 | 27 |
Pennsylvania Pricing in Context
In Pennsylvania, CPT code 81339 (Gene Analysis (mpl Proto-Oncogene, Thrombopoietin Receptor) Sequence Analysis Of Exon 10) carries an average Medicare payment of $181.50 — 0% above the national benchmark of $181.32. 6 providers across the state submitted claims for this procedure in 2023, performing 2.7K total services. Individual payments in PA ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.
The average billed charge in Pennsylvania is $190.40, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Pennsylvania sits above the national Medicare average, commercial rates in the state may also run higher than the US median.
Using RAND 2024 commercial-to-Medicare ratios for Genetic/Molecular Test procedures, the estimated commercial insurance price in Pennsylvania lands near $399.30, with self-pay cash prices typically around $188.49. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.
Frequently Asked Questions
How much does Gene Analysis (mpl Proto-Oncogene, Thrombopoietin Receptor) Sequence Analysis Of Exon 10 cost in Pennsylvania?
The average Medicare payment for Gene Analysis (mpl Proto-Oncogene, Thrombopoietin Receptor) Sequence Analysis Of Exon 10 in Pennsylvania is $181.50, which is 0% above the national average of $181.32. Providers in PA typically bill $190.40 for this procedure.
What does Gene Analysis (mpl Proto-Oncogene, Thrombopoietin Receptor) Sequence Analysis Of Exon 10 cost with insurance in Pennsylvania?
With commercial insurance in Pennsylvania, Gene Analysis (mpl Proto-Oncogene, Thrombopoietin Receptor) Sequence Analysis Of Exon 10 costs an estimated $399.30. Without insurance, the estimated cash price is $188.49. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.
How many providers perform Gene Analysis (mpl Proto-Oncogene, Thrombopoietin Receptor) Sequence Analysis Of Exon 10 in Pennsylvania?
6 providers in Pennsylvania billed Medicare for Gene Analysis (mpl Proto-Oncogene, Thrombopoietin Receptor) Sequence Analysis Of Exon 10 in 2023, performing 2.7K total services. Medicare payments ranged from N/A to N/A depending on the provider.
Is Gene Analysis (mpl Proto-Oncogene, Thrombopoietin Receptor) Sequence Analysis Of Exon 10 cheaper in Pennsylvania than the national average?
No — Gene Analysis (mpl Proto-Oncogene, Thrombopoietin Receptor) Sequence Analysis Of Exon 10 costs 0% above the national average in Pennsylvania. The state average Medicare payment is $181.50 compared to $181.32 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.
Related Guides
Related Data Sources
Data from CMS Medicare Physician & Other Practitioners (2023).
Read our methodology — how this data is sourced, computed, and verified.